332 related articles for article (PubMed ID: 23836471)
1. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
J Mol Recognit; 2013 Sep; 26(9):432-8. PubMed ID: 23836471
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Exp Cell Res; 2013 Nov; 319(18):2812-21. PubMed ID: 23896027
[TBL] [Abstract][Full Text] [Related]
3. Detecting CD20-rituximab specific interactions on lymphoma cells using atomic force microscopy.
Li M; Liu L; Xi N; Wang Y; Dong Z; Li G; Xiao X; Zhang W
Sci China Life Sci; 2010 Oct; 53(10):1189-95. PubMed ID: 20953941
[TBL] [Abstract][Full Text] [Related]
4. Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
J Microsc; 2014 Apr; 254(1):19-30. PubMed ID: 24499016
[TBL] [Abstract][Full Text] [Related]
5. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
[TBL] [Abstract][Full Text] [Related]
6. Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Scanning; 2013; 35(1):40-6. PubMed ID: 22890585
[TBL] [Abstract][Full Text] [Related]
7. Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy.
Li M; Xiao X; Liu L; Xi N; Wang Y
J Immunol Methods; 2016 Sep; 436():41-9. PubMed ID: 27374866
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
[TBL] [Abstract][Full Text] [Related]
9. [Distribution and force spectroscopy of CD20 antigen-antibody binding on the B cell surface].
Wang Q; Lu Y; Li S; Wang M; Cai J
Sheng Wu Gong Cheng Xue Bao; 2011 Jan; 27(1):131-6. PubMed ID: 21553499
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
11. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
12. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
14. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
15. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
16. Imaging and measuring the rituximab-induced changes of mechanical properties in B-lymphoma cells using atomic force microscopy.
Li M; Liu L; Xi N; Wang Y; Dong Z; Tabata O; Xiao X; Zhang W
Biochem Biophys Res Commun; 2011 Jan; 404(2):689-94. PubMed ID: 21156157
[TBL] [Abstract][Full Text] [Related]
17. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
18. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
